Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.
By T. Choueiri, S. Halabi, B. Sanford, O. Hahn, M. Michaelson, Meghara Walsh, D. Feldman, T. Olencki, J. Picus, E. Small and 3 more. Journal of Clinical Oncology, 2017
644 citations recorded by the source corpus.
Subfields: Molecular Biology, Oncology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/d62f49d3a2e23e7f00d1c5ec1ab8fedd8a6bb95c
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
In Oncology
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Treatment of renal cell carcinoma: Current status and future directions (2017, background): “Of note, cabozantinib was also tested in the front-line setting in a small, randomized, phase 2 trial comparing it with sunitinib (CABOSUN) in 157 patients who had intermediate-risk/poor-risk (IMDC criteria), previously untreated mRCC.(130) A longer PFS (8.”